Avalo Therapeutics (AVTX) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Opus Genetics (IRD) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 108.9% versus a loss of 62.1%. Over five years, IRD leads with a -8.3% price change compared with -99.9% for AVTX. Avalo Therapeutics is the larger company by market cap ($390.9 million vs $385.7 million), about 1.0 times the size, while Opus Genetics is growing revenue faster (+29.1% vs -86.6%).
Opus Genetics converts more of its revenue into profit, with a net margin of -349.3% versus -132642.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | IRD |
|---|---|---|
| Share price | $6.76 | $3.99 |
| Market cap | $390.88M | $385.65M |
| 1-day change | +0.15% | -2.21% |
| YTD return | -62.78% | +98.51% |
| 1-year return | -62.09% | +108.90% |
| 5-year return | -99.89% | -8.28% |
| EPS (TTM) | $-2.26 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | $14.20M |
| Revenue growth (YoY) | -86.62% | +29.15% |
| Net income (latest FY) | $-78.26M | $-49.59M |
| Operating margin | -123601.69% | -271.90% |
| Net margin | -132642.37% | -349.33% |
| 52-week high | $24.27 | $7.07 |
| 52-week low | $6.53 | $1.88 |
| Distance from 52-week high | -72.15% | -43.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +414.79% | +249.37% |
| Average volume | 1.80M | 2.56M |
| Shares outstanding | 57.82M | 96.65M |
| Employees | 33 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed AVTX by 171.0 percentage points over the past year.
- Opus Genetics is more profitable, keeping -349.3 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
- Opus Genetics grew revenue faster in its latest fiscal year (+29.15% vs -86.62%).
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
AVTX vs IRD FAQ
Which is bigger, Avalo Therapeutics or Opus Genetics?
Avalo Therapeutics (AVTX) is larger, with a market capitalization of $390.88M compared with $385.65M for Opus Genetics (IRD).
Which stock has performed better over the past year, AVTX or IRD?
IRD returned +108.90% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.